Поиск патентов

Настройки

Глубина выборки

Укажите год

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Ключевые слова. Может быть несколько по одной на строку

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка

Автор

Ведите корректный номера.

Владелец

Ведите корректный номера.

Классы IPC

Ведите корректный номера.

Классы CPC

Ведите корректный номера.

Начиная с года

Укажите год

Заканчивая годом

Укажите год

Применить Всего найдено 36789. Отображено 100.

05-01-2012 дата публикации

Compositions and methods for enhancing contrast in imaging

Номер: US20120003159A1

Автор: Ananth Annapragada, Ketankumar B. Ghaghada, Russell M. Lebovitz

Принадлежит: Marval Biosciences Inc, University of Texas System

Examples of compositions of liposomes and methods of making the same containing high concentrations of contrast-enhancing agents for computed tomography are provided. Example compositions of such liposomes, when administered to a subject, provide for increased contrast of extended duration, as measured by computed tomography, in the bloodstream and other tissues of the subject. Also provided are example methods for making the liposomes stable, that is, resistant to leakage of the contrast-enhancing agents, including the extrusion of the liposomes at high pressures and at high flow rates per total pore area of the extrusion filters.

Подробнее

Номер записи: 1

05-01-2012 дата публикации

Animal model for parkinson's disease

Номер: US20120005765A1

Автор: Michael Panneton, Vijaya Kumar, William Burke

Принадлежит: St Louis University

Disclosed are methods and compositions for an animal model of Parkinson's disease. In particular, disclosed is the use of antisense compounds to inhibit the expression of ALDH1A1 in the substantia nigra of an animal brain for the purpose of creating an animal that will displays the symptoms of a human with Parkinson's Disease, including various biochemical, histological, and behavioral characteristics. Also disclosed are methods for using the animal model for Parkinson's disease to test potential therapeutic agents for Parkinson's disease.

Подробнее

Номер записи: 2

12-01-2012 дата публикации

Gastrin releasing peptide compounds

Номер: US20120009122A1

Автор: Adrian D. Nunn, Edmund Marinelli, Enrico Cappelletti, Karen E. Linder, Kondareddiar Ramalingam, Luciano Lattuada, Michael F. Tweedle, Natarajan Raju, Palaniappa Nanjappan, Rolf E. Swenson

Принадлежит: BRACCO IMAGING SPA

New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is a metal chelator having the structure: wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

Подробнее

Номер записи: 3

02-02-2012 дата публикации

Methods for treating adult respiratory distress syndrome

Номер: US20120027742A1

Автор: Jahar Bhattacharya, Sadiqa K. Quadri, Shonit Das

Принадлежит: Columbia University of New York

We have discovered that the activated phosphorylated form of focal adhesion kinase (hereafter “FAKp”) strengthens the microvascular endothelial cell (EC) junctions that form a barrier in pulmonary endothelia, and the increased barrier helps to prevent acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Thus certain embodiments of the invention are directed to prevention and treatment of ALI and ARDS by administering a therapeutically effective amount of FAKp to subjects at risk of developing or diagnosed as having either ALI or ARDS.

Подробнее

Номер записи: 4

09-02-2012 дата публикации

Artificial cells

Номер: US20120034155A1

Автор: Elizabeth A. Sweeney, Gary L. McKnight, Lowell L. Wood, JR., Muriel Y. Ishikawa, Roderick A. Hyde, Wayne R. Kindsvogel

Принадлежит: SEARETE LLC

The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products.

Подробнее

Номер записи: 5

09-02-2012 дата публикации

Artificial cells

Номер: US20120034157A1

Автор: Elizabeth A. Sweeney, Gary L. McKnight, Lowell L. Wood, JR., Muriel Y. Ishikawa, Roderick A. Hyde, Wayne A. Kindsvogel

Принадлежит: SEARETE LLC

The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products.

Подробнее

Номер записи: 6

16-02-2012 дата публикации

Anti-Hemagglutinin Antibody Compositions And Methods Of Use Thereof

Номер: US20120039899A1

Автор: Andres G. Grandea, III, Christina L. Boozer, Ole Olsen

Принадлежит: Theraclone Sciences Inc

The present invention provides novel human anti-Influenza antibodies and related compositions and methods. These antibodies are used in the prevention, inhibition, neutralization, diagnosis, and treatment of influenza infection.

Подробнее

Номер записи: 7

01-03-2012 дата публикации

Composition and a method for producing contrast agent using the composition

Номер: US20120052011A1

Автор: Kouichi Kato, Satoshi Yuasa, Tatsuki Fukui

Принадлежит: Canon Inc

A composition including a hydrophilic dye having a sulfonate group and a hydrophobic solvent, wherein the composition includes at least one of a nicotinic acid derivative and a tiamine derivative, can form densely accumulated particles and the like since the composition includes a hydrophilic dye that is likely to dissolve in a hydrophobic solvent.

Подробнее

Номер записи: 8

15-03-2012 дата публикации

Uniform Fluorescent Microspheres with Hydrophobic Surfaces

Номер: US20120064012A1

Автор: Yu-zhong Zhang

Принадлежит: Life Technologies Corp

Fluorescent microspheres for the measurement of blood flow are provided. The microspheres are substantially uniform in diameter and have a hydrophobic surface, which allows them to circulate more freely throughout bloodstream, while reducing immunogenicity, particle aggregation and bioaccumulation. The hydrophobic surface on each microsphere is generally comprised of polymeric material having a limited surface charge.

Подробнее

Номер записи: 9

15-03-2012 дата публикации

Fluorescent mri probe

Номер: US20120065384A1

Автор: Kenjiro Hanaoka, Takehiro Yamane, Tetsuo Nagano, Yasuaki Muramatsu

Принадлежит: University of Tokyo NUC

A fluorescent gadolinium complex compound comprising a residue of gadolinium.1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid or a residue of gadolinium.diethylenetriaminepentaacetic acid bound covalently with a group represented by the following general formula (I) (R 1 represents hydrogen atom or a substituent R 2 , R 4 , R 5 and R 7 represent hydrogen atom, a halogen atom or a C 1-6 alkyl group, and R 3 and R 6 represent hydrogen atom, a halogen atom or a C 1-6 alkyl group), which is easily taken up into cells and useful as a probe observable by the fluorescence method and MRI.

Подробнее

Номер записи: 10

22-03-2012 дата публикации

Complex and contrast agent for photoimaging using the same

Номер: US20120070375A1

Автор: Jun-ichiro Jo, Masato Minami, Mie Morita, Satoshi Yuasa, Tetsuya Yano, Yasuhiko Tabata, Yoshinori Tomida

Принадлежит: Canon Inc

There is provided a gelatin-ICG complex that can suppress leakage of ICG included therein. The complex has a gelatin derivative including at least one of a phospholipid covalently bonded to a gelatin or a cholesterol covalently bonded to a gelatin, and indocyanine green.

Подробнее

Номер записи: 11

22-03-2012 дата публикации

Fluorescent conjugated polymers with a bodipy-based backbone and uses thereof

Номер: US20120070382A1

Автор: Haiying Liu

Принадлежит: MICHIGAN TECHNOLOGICAL UNIVERSITY

The present invention provides various fluorescent conjugated polymers with a BODIPY-based backbone. The invention also provides methods of using the polymers of the invention, such as for imaging and detection of cells, tumors, bacteria and viruses.

Подробнее

Номер записи: 12

29-03-2012 дата публикации

Post-biopsy cavity treatment implants and methods

Номер: US20120076733A1

Автор: Ary S. Chernomorsky, James W. Vetter, Simon Chernomorsky

Принадлежит: Chernomorsky Ary S, Simon Chernomorsky, VETTER JAMES W

A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix defining a first controlled pore architecture. The shell portion is coupled to the core portion and includes a second porous matrix defining a second controlled pore architecture that is different from the first controlled pore architecture.

Подробнее

Номер записи: 13

29-03-2012 дата публикации

Hierarchical chromonic structures

Номер: US20120077022A1

Автор: Cristin E. Moran, Hassan Sahouani, Sanat Mohanty

Принадлежит: 3M Innovative Properties Co

A method of making a chromonic structure comprises (a) preparing a first aqueous mixture comprising (i) a continuous water-soluble polymer phase and (ii) a discontinuous chromonic phase comprising a chromonic material, to form chromonic nanoparticles; (b) non-covalently crosslinking the resulting chromonic nanoparticles with a multivalent cation salt; (c) dispersing the resulting crosslinked chromonic nanoparticles in a water-soluble polymer phase to form a chromonic nanoparticle dispersion; and (d) preparing a second aqueous mixture comprising (i) the chromonic nanoparticle dispersion and (ii) a continuous chromonic phase comprising a chromonic material.

Подробнее

Номер записи: 14

05-04-2012 дата публикации

Corneal treatment system and method

Номер: US20120083772A1

Автор: Raymond A. Hartman, Roy Scott Rubinfeld, Sandy T. Feldman

Принадлежит: CURVERIGHT LLC

A system for bilateral or monocular photochemical cross-linking of corneal collagen employs selectable light in a selected wavelength band as the excitation source and riboflavin as the photosensitizer. The system has an illumination source which may have multi-spectral capability, light guides for delivery of light to the optical head for projection onto the corneal surface, selectable radiation patterns to accommodate individual corneal architecture, and red light phototherapy to limit apoptosis and accelerate healing time. Aiming beams provide alignment of the optical head to the patient cornea. A microprocessor-controlled rotary solenoid mechanical shutter provides discontinuous illumination for tissue reoxygenation, and devices and methods may be included for the in situ determination of oxygen utilization and the riboflavin content of the cornea.

Подробнее

Номер записи: 15

12-04-2012 дата публикации

Gadolinium expressed lipid nanoparticles for magnetic resonance imaging

Номер: US20120087857A1

Автор: John D. Hoekman, Ken Maravilla, Rodney J.Y. Ho

Принадлежит: UNIVERSITY OF WASHINGTON

Lipid nanoparticles expressing metal ions and methods for using the compositions for magnetic resonance imaging.

Подробнее

Номер записи: 16

12-04-2012 дата публикации

Method for the Generation of Nuclear Hyper-Antipolarization in Solids Without the Use of High Magnetic Fields or Magnetic Resonant Excitation

Номер: US20120087867A1

Автор: Christoph Boehme, Dane R. McCamey, Gavin W. Morley, Johan van Tol

Принадлежит: Individual

A method of inducing nuclear spin hyper-antipolarization in a solid material is disclosed and described. The solid material can be subjected to an ultralow temperature and a magnetic field. The solid material can include donor nuclei and a carrier material while the material also has both a nuclear spin and an electron spin which are coupled sufficiently to allow an Overhauser effect. The solid material can be subjected at the ultralow temperature to a light source for a time sufficient to induce a substantial nuclear spin antipolarization in the solid material and form a nuclear spin hyper-antipolarized material. The ultralow temperature and light source are controlled so as to be sufficient to drive a non-equilibrium nuclear Overhauser effect of hyperfine coupled electron and nuclear spins. The resulting nuclear spin hyper-antipolarized material can be used for a variety of applications such as medical imaging and quantum computing. These materials can be readily formed relatively quickly and are generally stable at room temperatures.

Подробнее

Номер записи: 17

12-04-2012 дата публикации

Method and system for determining whether a drug will be effective on a patient with a disease

Номер: US20120089341A1

Автор: Heinrich Röder, Julia Grigorieva, Maxim Tsypin

Принадлежит: Biodesix Inc

A process of determining whether a patient with a disease or disorder will be responsive to a drug, used to treat the disease or disorder, including obtaining a test spectrum produced by a mass spectrometer from a serum produced from the patient. The test spectrum may be processed to determine a relation to a group of class labeled spectra produced from respective serum from other patients having the or similar clinical stage same disease or disorder and known to have responded or not responded to the drug. Based on the relation of the test spectrum to the group of class labeled spectra, a determination may be made as to whether the patient will be responsive to the drug.

Подробнее

Номер записи: 18

19-04-2012 дата публикации

Molecularly Imprinted Polymers for Use as Imaging and Therapeutics Agents

Номер: US20120093720A1

Автор: Robert Jones, Thomas Beck

Принадлежит: Individual

The invention described herein provides biocompatible molecularly imprinted polymers (MIPs) that are non-toxic, water soluble, small molecular weight, and degradable in a living body. The MIPs are capable of binding to all or a portion of a specific target macromolecule associated with a disease located within the living body and they are derivatized for stealth for in vivo applications to avoid the reticuloendothelial system. The MIPs of the invention are functionalized to an amine or carboxyl group and are derivatized with an imaging and/or therapeutic agent for taking images of the disease and/or for providing therapy. The macromolecule can be selected from a group consisting of proteins, glycoproteins, lipoproteins, peptidoglycans, peptides, polypeptides, polynucleotides, and polysaccharides. The invention described herein also provides methods and kits wherein MIPs of the invention can be employed as targeted imaging and therapeutic agents.

Подробнее

Номер записи: 19

19-04-2012 дата публикации

Methods for detection, diagnosis and selective eradication of neoplasms in vivo using multidomain biotags

Номер: US20120095387A1

Автор: Marek Małecki, Raf Malecki

Принадлежит: Individual

A method for treating cancer in a subject is provided, the method comprising administering to the subject an effective dose of a multidomain biotag that targets one or more cancer cells; and exposing the subject to one or more rounds of radiation. The one or more rounds of radiation kills the one or more cancer cells targeted by the biotag, but, in general, do not kill healthy cells or kills a negligible number of healthy cells.

Подробнее

Номер записи: 20

03-05-2012 дата публикации

Multivalent pcv2 immunogenic compositions and methods of producing such compositions

Номер: US20120107348A1

Автор: Greg Nitzel, Marc Eichmeyer, Michael Roof, Phillip Hayes

Принадлежит: Boehringer Ingelheim Vetmedica Inc

An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine,

Подробнее

Номер записи: 21

10-05-2012 дата публикации

Optical imaging agents

Номер: US20120114563A1

Автор: Anup Sood, Brian Duh-Lan Lee, Jason William Castle, Kenneth Michael Fish, Natalie Anne Staples, Randall Lee Carter

Принадлежит: General Electric Co

The present invention relates to a method of in vivo optical imaging, of the margins around tumours, which comprises an optical imaging contrast agent. The optical imaging agents comprise conjugates of near-infrared dyes with synthetic polyethylene glycol (PEG) polymers having a molecular weight in the range 15-45 kDa. Also disclosed are optical imaging contrast agents, pharmaceutical compositions and kits.

Подробнее

Номер записи: 22

17-05-2012 дата публикации

Antibodies that immunospecifically bind to b lymphocyte stimulator protein

Номер: US20120121606A1

Автор: David Hilbert, Gil H. Choi, Steven C. Barash, Steven M. Ruben, Tristan Vaughan

Принадлежит: Human Genome Sciences Inc

The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.

Подробнее

Номер записи: 23

24-05-2012 дата публикации

Skin Permeating And Cell Entering (SPACE) Peptides and Methods of Use Thereof

Номер: US20120128756A1

Автор: Samir M. Mitragotri, Tracy Hsu

Принадлежит: UNIVERSITY OF CALIFORNIA

The present disclosure provides peptides and peptide compositions, which facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (SC) and/or the cellular membranes of viable cells.

Подробнее

Номер записи: 24

31-05-2012 дата публикации

Peptides whose uptake in cells is controllable

Номер: US20120134922A1

Автор: Emilia Olson, Mike Whitney, Quyen Nguyen, Roger Tsien, Tao Jiang

Принадлежит: UNIVERSITY OF CALIFORNIA

Disclosed herein, in certain embodiments, is a selective transport molecule with increased in vivo circulation. In some embodiments, a selective transport molecule disclosed herein has the formula (A—X—B—C)n—M, wherein C is a cargo moiety; A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X is a linker; and M is a macromolecular carrier.

Подробнее

Номер записи: 25

21-06-2012 дата публикации

Targeting agent to newly formed blood vessels

Номер: US20120156132A1

Автор: Kentaro Nakamura, Yasuhiko Tabata

Принадлежит: Fujifilm Corp, KYOTO UNIVERSITY

It is an object of the present invention to provide a targeting agent that enables drug delivery to a neovascular site and the imaging of such a neovascular site, utilizing the effect of the agent to accumulate in the neovascular site. The present invention provides a targeting agent to a neovascular site, which comprises a gelatin-like protein.

Подробнее

Номер записи: 26

05-07-2012 дата публикации

Arginase Inhibitors and Methods of Use Thereof

Номер: US20120171116A1

Автор: Bhaskara Rao Nallaganchu, Bruce Edward Tomczuk, Gary Lee Olson, Jane Wang, Richard Scott Pottorf

Принадлежит: Corridor Pharmaceuticals Inc

The present invention includes arginase enzyme inhibitors, compositions comprising these arginase inhibitors, and methods of treating or diagnosing conditions characterized either by abnormally high arginase activity or abnormally low nitric oxide levels in a mammal, comprising administering compositions of the invention to the mammal.

Подробнее

Номер записи: 27

12-07-2012 дата публикации

Compositions, methods, and systems comprising fluorous-soluble polymers

Номер: US20120177578A1

Автор: Jeewoo Lim, Timothy M. Swager, Yohei Takeda

Принадлежит: Massachusetts Institute of Technology

The present invention generally relates to compositions, methods, and systems comprising polymers that are fluorous-soluble and/or organize at interfaces between a fluorous phase and a non-fluorous phase. In some embodiments, emulsions or films are provided comprising a polymer. The polymers, emulsions, and films can be used in many applications, including for determining, treating, and/or imaging a condition and/or disease in a subject. The polymer may also be incorporated into various optoelectronic device such as photovoltaic cells, organic light-emitting diodes, organic field effect transistors, or the like. In some embodiments, the polymers comprise pi-conjugated backbones, and in some cases, are highly emissive.

Подробнее

Номер записи: 28

19-07-2012 дата публикации

Heart-slowing drug containing short-acting beta-blocker as teh active ingredient

Номер: US20120184545A1

Автор: Ken Mizushima, Kenzo Nakao, Masaharu Hirano, Morito Akisada, Takahiro Azuma

Принадлежит: Ono Pharmaceutical Co Ltd

The present invention relates to an agent which slows down the heart rate which has an excellent controlling ability in diagnostic imaging comprising a short-acting β-blocker (e.g. landiolol hydrochloride or esmolol hydrochloride). The short-acting β-blocker has a property of slowing down the heart rate and it can temporarily suppress the tachycardia at diagnosis. According to the dose and the method of administration, it can control the period for the heart rate adjustment. Also, the present invention relates to a diagnostic imaging auxiliary comprising a short-acting β-blocker as active ingredient.

Подробнее

Номер записи: 29

26-07-2012 дата публикации

Orally administered bacteria as vehicles for systematic delivery of agents

Номер: US20120189550A1

Автор: Douwe Van Sinderen, Gerald O'Sullivan, Mark Tangney, Michelle Cronin

Принадлежит: University College Cork

The current invention relates to the use of a bacterial species in the preparation of a composition adapted for oral administration for the delivery of an agent to a site in the body. The site in the body may be an organ or a tumour site. The bacterial species is a food grade, non-pathogenic, gram-positive bacteria capable of anaerobic growth.

Подробнее

Номер записи: 30

26-07-2012 дата публикации

Compositions and methods using microspheres and non-ionic contrast agents

Номер: US20120189552A1

Автор: Philippe Reb

Принадлежит: Biosphere Medical SA

The present invention relates to compositions and methods for treating diseases and disorders including cancer and various other angiogenic-dependent diseases, vascular malfunctions, arteriovenous malformations (AVM), hemorrhagic processes and treatment of pain, in particular tumor-related pain by drug delivery and/or therapeutic embolization using microspheres. More particularly the invention relates to microspheres containing non-ionic contrast agents, to compositions comprising these microspheres, as well as methods for preparing and using such compositions for embolization therapy. The invention further relates to compositions and methods using detectable microspheres for targeted drug delivery, irrespective of whether embolization is also needed.

Подробнее

Номер записи: 31

26-07-2012 дата публикации

Treatment and prophylaxis of amyloidosis

Номер: US20120189624A1

Автор: Dale B. Schenk, Jonathan Wall, Jose W. Saldanha, Peter A. Seubert

Принадлежит: Elan Pharmaceuticals LLC

Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.

Подробнее

Номер записи: 32

02-08-2012 дата публикации

Myocardial perfusion imaging methods and compositions

Номер: US20120195827A1

Автор: Luiz Belardinelli, Mitchell Rosner

Принадлежит: Gilead Sciences Inc

A myocardial imaging method that is accomplished by administering one or more adenosine A 2A adenosine receptor agonist to a human undergoing myocardial imaging as well as pharmaceutical compositions comprising at least one A 2a receptor agonist, at least one liquid carrier, and at least one co-solvent.

Подробнее

Номер записи: 33

02-08-2012 дата публикации

Tumor tissue-selective bio-imaging nanoparticles

Номер: US20120195835A1

Автор: Kyoungja Woo, Myung-Ik YOO

Принадлежит: Korea Advanced Institute of Science and Technology KAIST

A bio-imaging nanoparticle is composed of a core nanoparticle, a bonding layer having organic ligands, surfactants and polyoxyalkylene derivatives of fatty acid ester, and veiling the core nanoparticle, and functional molecules, wherein the organic ligands are bound to a surface of the core nanoparticle, the surfactants are bound to a portion of the surface of the core nanoparticle to which the organic ligands are not bound, the polyoxyalkylene derivatives of the fatty acid ester are introduced in an empty space between the organic ligands and the surfactants of the bonding layer, and the functional molecule is bound to a second terminal end opposite to a first terminal end of both terminal ends of the organic ligand, the first terminal end of the organic ligand being bound to a shell of the core nanoparticle.

Подробнее

Номер записи: 34

02-08-2012 дата публикации

Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation

Номер: US20120196898A1

Автор: Rusiko Bourtchouladze, Thomas M. Hallam, Tim Tully

Принадлежит: Individual

The present invention provides methods of improving cognitive and motor deficits associated with central nervous system (CNS) disorder or condition in an animal. The methods comprise a general administration of phosphodiesterase 4 inhibitors and optionally training the animal under conditions sufficient to produce an improvement in performance.

Подробнее

Номер записи: 35

09-08-2012 дата публикации

Foxc1 antibodies and methods of their use

Номер: US20120201752A1

Автор: Xiaojiang Cui

Принадлежит: Individual

In one embodiment, an isolated antibody or functional fragment thereof which binds an antigenic peptide sequence of human FOXC1 is provided herein. Such antibodies or functional fragments may be used to diagnose, prognose or treat basal-like breast cancer. The antibody or functional fragment may be a monoclonal antibody produced by a hybridoma cell line. Thus, a hybridoma cell line that produces a FOXC1 monoclonal antibody which binds an antigenic peptide sequence of human FOXC1 as described above is also provided.

Подробнее

Номер записи: 36

09-08-2012 дата публикации

Dual small molecule inhibitors of cancer and angiogenesis

Номер: US20120202800A1

Автор: Milton L. Brown

Принадлежит: UNIVERSITY OF VIRGINIA PATENT FOUNDATION

The present invention provides analogs and derivatives of thalidomide which inhibit cancer and angiogenesis. The present invention further provides compounds which disrupt microtubule polymerization. The present further provides methods of treating cancers comprising mutant p53.

Подробнее

Номер записи: 37

16-08-2012 дата публикации

Modified Variable Domain Molecules And Methods For Producing And Using Same

Номер: US20120207673A1

Автор: Daniel Christ, Kip Dudgeon

Принадлежит: GARVAN INSTITUTE OF MEDICAL RESEARCH

The present disclosure provides an isolated protein comprising an antibody heavy chain variable region (V H ) comprising a negatively charged amino acid at position 28 and/or 31 and/or 32 and/or 33 and/or 35 according to the numbering system of Kabat, the protein capable of binding specifically to an antigen.

Подробнее

Номер записи: 38

16-08-2012 дата публикации

Bioactivation of particles

Номер: US20120208023A1

Автор: David King, Fabien Pinaud, Shimon Weiss

Принадлежит: UNIVERSITY OF CALIFORNIA

Particles are bioactivated by attaching bioactivation peptides to the particle surface. The bioactivation peptides are peptide-based compounds that impart one or more biologically important functions to the particles. Each bioactivation peptide includes a molecular or surface recognition part that binds with the surface of the particle and one or more functional parts. The surface recognition part includes an amino-end and a carboxy-end and is composed of one or more hydrophobic spacers and one or more binding clusters. The functional part(s) is attached to the surface recognition part at the amino-end and/or said carboxy-end.

Подробнее

Номер записи: 39

30-08-2012 дата публикации

Optical imaging probes, optical imaging systems, methods of optical imaging, and methods of using optical imaging probes

Номер: US20120220870A1

Автор: Hongguang Liu, Sanjiv S. Gambhir, Sri-Rajasekhar Kothapalli, Zhen Cheng

Принадлежит: Leland Stanford Junior University

Embodiments of the present disclosure provide for radionuclide probes, methods of using the radionuclide probes, methods of detecting an optical signal from radionuclides, methods of detecting an optical signal from a quantum dot(s) that receives optical energy from a radionuclide(s), system for analyzing optical energy emitted by a radionuclide(s), system for imaging a target within a living subject or a sample, methods of imaging a disease or condition, and the like.

Подробнее

Номер записи: 40

04-10-2012 дата публикации

Dyes for Membranes and Biological Structures

Номер: US20120251458A1

Автор: Acacio Alves de Souza Lima Filho, Diogo de Sousa Martins, Mauricio MAIA, Rubens Belfort, JR.

Принадлежит: Kemin Industries Inc

The present invention relates to the use of one or more natural dyes, alone or in combination with other dyes for preparation of a composition to stain membranes and biological structures, in order to facilitate their identification during surgical procedures. The present invention relates to the use of one or more natural dyes, alone or in combination with other dyes, to stain membranes and biological structures, in order to facilitate their identification during surgical procedures.

Подробнее

Номер записи: 41

11-10-2012 дата публикации

Linkable Lewis X Analogs

Номер: US20120258043A1

Автор: Edmund R. Marinelli, Kondareddiar Ramalingam, Radhakrishna Pillai, Ramachandran Ranganathan, Rolf E. Swenson

Принадлежит: Bracco Suisse SA

Disclosed herein is a class of linkable tetrasaccharide compounds that includes the amino phenyl glycoside of sialyl Lewis X (SLe X ) and related analogs. These compounds have conjugatable nucleophilic groups, making them useful in preparing multimeric SLe X compositions. In particular, the disclosed SLe X compounds can be used to prepare selectin binding ligand conjugates by linking them to a reporter moiety, such as a contrast agent, a radiodiagnostic agent, or a cytotoxic or chemotherapeutic agent. The SLe X compounds and conjugates of the invention exhibit binding to selectin that is similar to native Sialyl Le X , and are, therefore, useful for diagnosing and treating selectin-mediated disorders and related conditions.

Подробнее

Номер записи: 42

25-10-2012 дата публикации

Intracellular Delivery of Contrast Agents with Functionalized Nanoparticles

Номер: US20120269730A1

Автор: Chad A. Mirkin, Thomas J. Meade, Xiaoyang Xu, Ying Song

Принадлежит: Northwestern University

The present invention is directed to compositions and methods for intracellular delivery of a contrast agent with a functionalized nanoparticle.

Подробнее

Номер записи: 43

25-10-2012 дата публикации

Micellar compositions for use in biological applications

Номер: US20120269736A1

Автор: Mark Green, Philip Howes

Принадлежит: KINGS COLLEGE LONDON

This invention relates to a composition comprising a micelle for use in biological applications, the micelle comprising: a substantially water-insoluble conjugated polymer which exhibits luminescence or fluorescence from about 300 nm to about 1500 nm of the electromagnetic spectrum: a biocompatible surfactant and/or lipid: and a MRI active agent.

Подробнее

Номер записи: 44

01-11-2012 дата публикации

Treatment and Diagnosis of Macrophage Mediated Disease

Номер: US20120276191A1

Автор: Mary Jo Turk, Philip S. Low

Принадлежит: Individual

The invention relates to a method of treating or monitoring/diagnosing a disease state mediated by activated macrophages. The method comprises the step of administering to a patient suffering from a macrophage mediated disease state an effective amount of a composition comprising a conjugate or complex of the general formula A b -X where the group A b comprises a ligand capable of binding to activated macrophages, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering macrophage function, and when the conjugate is being used for monitoring/diagnosing the disease state, X comprises an imaging agent. The method is useful for treating a patient suffering from a disease selected from the group consisting of rheumatoid arthritis, ulcerative colitis, Crohn's disease, inflammation, infections, osteomyelitis, atherosclerosis, organ transplant rejection, pulmonary fibrosis, sarcoidosis, and systemic sclerosis.

Подробнее

Номер записи: 45

08-11-2012 дата публикации

Methods for measuring the metabolism of neurally derived biomolecules in vivo

Номер: US20120282642A1

Автор: David Michael Holtzman, Randall John Bateman

Принадлежит: Washington University in St Louis WUSTL

The present invention relates to methods of diagnosing, monitoring, and assessing treatment effects for neurological and neurodegenerative diseases and disorders, such as Alzheimer's Disease, early in the course of clinical disease or prior to the onset of brain damage and clinical symptoms. Methods of measuring the in vivo metabolism of biomolecules produced in the CNS in a subject are provided.

Подробнее

Номер записи: 46

15-11-2012 дата публикации

Rare earth nanoparticles

Номер: US20120288535A1

Автор: Chittaranjan Patra, Debabrata Mukhopadhyay, Nicholas E. Vlahakis, Priyabrata Mukherjee, Resham Bhattacharya

Принадлежит: Mayo Foundation for Medical Education and Research

This document provides methods and materials related to rare earth particles such as rare earth nanorods (e.g., inorganic lanthanide hydroxide nanorods). For example, rare earth (e.g., lanthanide) particles such as europium hydroxide nanorods, methods and materials for making rare earth particles (e.g., europium hydroxide nanorods), and methods and materials for using rare earth particles (e.g., europium hydroxide nanorods) as an imaging agent and/or to promote angiogenesis are provided.

Подробнее

Номер записи: 47

22-11-2012 дата публикации

Antagonists of il-6 to raise albumin and/or lower crp

Номер: US20120294852A1

Автор: Jeffrey T.L. Smith

Принадлежит: ALDERBIO HOLDINGS LLC

The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.

Подробнее

Номер записи: 48

29-11-2012 дата публикации

Targeting and in vivo imaging of tumor-associated macrophages

Номер: US20120301394A1

Автор: Damya Laoui, Geert Raes, Jo Van Ginderachter, Kiavash Movahedi, Nick Devoogdt, Patrick De Baetselier, Steve Schoonooghe, Tony Lahoutte

Принадлежит: Vlaams Instituut voor Biotechnologie VIB

The invention relates to activities and characteristics of tumor-associated macrophages (TAMs). In particular, immunoglobulin single variable domains are provided against markers of TAMs, and methods using the same for in vivo imaging of tumor cells, as well as cancer diagnostics and therapeutics.

Подробнее

Номер записи: 49

29-11-2012 дата публикации

Hydrogels that undergo volumetric expansion in response to changes in their environment and their methods of manufacture and use

Номер: US20120302654A1

Автор: Gregory M. Cruise, Michael J. Constant

Принадлежит: MicroVention Inc

Generally, hydrogels are prepared by forming a liquid reaction mixture that contains a) monomer(s) and/or polymer(s) at least portion(s) of which are sensitive to environmental changes (e.g., changes in pH or temperature), b) a crosslinker and c) a polymerization initiator. If desired, a porosigen may be incorporated into the liquid reaction mixture to create pores. After the hydrogel is formed, the porosigen is removed to create pores in the hydrogel. These hydrogels may be prepared in many forms including pellets, filaments, and particles. Biomedical uses of these hydrogels include applications wherein the hydrogel is implanted in the body of a patient and an environmental condition at the implantation site causes the hydrogel to expand in situ.

Подробнее

Номер записи: 50

06-12-2012 дата публикации

In-situ intervertebral fusion device and method

Номер: US20120310352A1

Автор: John D. Malone, Thomas M. DiMauro

Принадлежит: DePuy Spine LLC

An orthopedic device for implanting between adjacent vertebrae comprising: an arcuate balloon and a hardenable material within said balloon. In some embodiments, the balloon has a footprint that substantially corresponds to a perimeter of a vertebral endplate. An inflatable device is inserted through a cannula into an intervertebral space and oriented so that, upon expansion, a natural angle between vertebrae will be at least partially restored. At least one component selected from the group consisting of a load-bearing component and an osteobiologic component is directed into the inflatable device through a fluid communication means.

Подробнее

Номер записи: 51

20-12-2012 дата публикации

Treatment and prophylaxis of amyloidosis

Номер: US20120321555A1

Автор: Dale B. Schenk, Jonathan Wall, Jose W. Saldanha, Peter A. Seubert

Принадлежит: Elan Pharmaceuticals LLC, UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.

Подробнее

Номер записи: 52

20-12-2012 дата публикации

Crosslinked Hydrogels and Related Method of Preparation

Номер: US20120321585A1

Автор: Fengfu Li, Jae-Il Ahn, May Griffith

Принадлежит: OTTAWA HEALTH RESEARCH INSTITUTE, UNIVERSITY OF OTTAWA

The present invention provides a method of manufacturing a hydrogel comprising the step of crosslinking a biopolymer using a carbodiimide crosslinker of Formula I wherein at least one of R 1 and R 2 is a functional group that is a bulky organic functional group. R 1 and R 2 can each independently be an optionally substituted saturated or unsaturated functional group selected from the group consisting of an alkyl, a cycloalkyl, a heterocyclic, and an aryl. The bulky organic functional group will slow down the crosslinking reaction of carbodiimide due to the steric effects and/or electronic effects, in comparison to a crosslinking reaction using EDC. Also provided are the hydrogels and ophthalmic devices prepared using the method of the invention and uses thereof.

Подробнее

Номер записи: 53

03-01-2013 дата публикации

Adenosine derivative formulations for medical imaging

Номер: US20130004426A1

Автор: Ajit B. Thakur, Dianne D. Zdankiewicz, Hsun-Wen Hsu, James E. Anderson, James F. Castner

Принадлежит: Forest Laboratories Holdings Ltd

A stable composition useful for myocardial perfusion imaging contains one or more 2-alkynyladenosine derivatives; and a solvent which is made up of water and hydroxypropyl-β-cyclodextrin.

Подробнее

Номер записи: 54

03-01-2013 дата публикации

Use of a neurofilament peptide for the treatment of glioma

Номер: US20130004429A1

Автор: Alan Peterson, Joel Eyer, Julien Balzeau, Raphael Berges

Принадлежит: McGill University, MEDICALE (INSERM) and ROYAL INSTITUTION FOR ADVANCEMENT OF, Universite dAngers

The present invention provides a new drug to treat malignant glioma, which is the most prevalent type of primary tumor of the central nervous system (CNS). The present invention indeed shows that the isolated NFL-TBS 40-63 peptide is highly specific for glioma cells, in which it triggers apoptosis. It is therefore presented here for use in a method for treating malignant glioma. The present invention further relates to the use of the NFL-TBS 40-63 peptide for detecting specifically glioma cells either in vivo, or in vitro, or for addressing chemical compounds to said tumor cells.

Подробнее

Номер записи: 55

10-01-2013 дата публикации

Compositions and methods comprising magnetic resonance contrast agents

Номер: US20130011340A1

Автор: Jiyoun Lee, Preeti A. Sukerar, Teresa K. Woodruff, Thomas J. Meade

Принадлежит: Northwestern University

The present invention relates to compositions and methods for imaging with magnetic resonance contrast agents. In particular, the present invention provides targeted contrast agents for selective imaging.

Подробнее

Номер записи: 56

24-01-2013 дата публикации

DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS

Номер: US20130022551A1

Автор: Nelson Ruiz-Opazo, Victoria L.M. Herrera

Принадлежит: Boston University

Provided herein are novel compositions comprising DEspR-specific antagonists and agonists, and methods of their use in a variety of therapeutic applications. The compositions comprising the DEspR-specific anatgonists and agonists described herein are useful in therapeutic, diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo-non invasive imaging and/or assessments.

Подробнее

Номер записи: 57

24-01-2013 дата публикации

Topical Compositions and Methods of Detection and Treatment

Номер: US20130022685A1

Автор: Amanda Nelson, James C. Crookston, Jason J. Benkoski, Jennifer L. Breidenich, Jennifer L. Sample, Joshua T. Wolfe, Julia B. Patrone, Le Huong, Lisa A. Kelly, Luis Garza, Marcia W. Patchan, Mellisa L. Theodore, Sewon Kang, Xiomara Calderon-Colon

Принадлежит: JOHNS HOPKINS UNIVERSITY

A topical composition includes a nanoemulsion of a plurality of hydrophobic particles having a hydrophilic coating therein. The hydrophobic particles are derived from the same or different hydrophobic material and each hydrophobic particle has a melting point below the melting point of the respective hydrophobic material. The hydrophobic particles comprise a mean particle size of less than about 10 nm, and the nanoemulsion further includes one or more pharmaceutically active agents.

Подробнее

Номер записи: 58

24-01-2013 дата публикации

Genetically modified mice and engraftment

Номер: US20130022996A1

Автор: Andrew J. Murphy, Anthony Rongvaux, Elizabeth Eynon, Jorge Galan, Markus Manz, Richard Flavell, Sean Stevens, Tim Willinger

Принадлежит: Institute for Research in Biomedicine IRB, Regeneron Pharmaceuticals Inc, YALE UNIVERSITY

A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mII2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/II2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.

Подробнее

Номер записи: 59

31-01-2013 дата публикации

Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue and/or fever

Номер: US20130028860A1

Автор: Jeffrey T.L. Smith, John A. Latham, Mark Litton, Randall Schatzman

Принадлежит: Individual

The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.

Подробнее

Номер записи: 60

14-02-2013 дата публикации

Fluorescent silica-based nanoparticles

Номер: US20130039848A1

Автор: Andrew Burns, Hoosweng Ow, Jason Lewis, Michelle Bradbury, Oula Penate Medina, Steven Larson, Ulrich Wiesner

Принадлежит: CORNELL UNIVERSITY, SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH

The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as polyethylene glycol) (PEG) The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo The nanoparticle may further be conjugated to a ligand capable of binding to a cellular component associated with the specific cell type, such as a tumor marker A therapeutic agent may be attached to the nanoparticle Radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle to permit the nanoparticle to be detectable by various imaging techniques.

Подробнее

Номер записи: 61

14-02-2013 дата публикации

Dye Conjugated Peptides for Fluorescent Imaging

Номер: US20130039861A1

Автор: Celeste Aida S. Regino, Chien-Hsing Chang, David M. Goldenberg, William J. Mcbride

Принадлежит: Immunomedics Inc

The present application discloses compositions and methods of use of dye conjugated peptides for fluorescent detection, diagnosis and/or imaging. In preferred embodiments, the compositions comprise a DNL complex comprising an anti-hapten antibody or antigen-binding fragment thereof conjugated to an AD moiety and a DDD moiety conjugated to an antibody or antigen-binding fragment thereof that binds to the target antigen, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety to form the DNL complex. More preferably, the compositions comprise a targetable construct comprising at least one hapten and a fluorescent probe. Binding of the DNL complex to the target antigen and of the hapten on the targetable construct to the DNL complex results in fluorescent labeling of the target antigen. Most preferably, fluorescent imaging is of use in intraoperative, intraperitoneal, laparoscopic, endoscopic or intravascular procedures for detection of diseased tissues.

Подробнее

Номер записи: 62

21-02-2013 дата публикации

Benzocyanine compounds

Номер: US20130045488A1

Автор: Boguslawa Dworecki, Frank G. Lehmann, Greg Hermanson, Marie Christine Nlend, Matthias S. Wenzel, Peter T. Czerney, Surbhi Desai

Принадлежит: Dyomics GmbH, Pierce Biotechnology Inc

Compounds useful as labels with properties comparable to known fluorescent compounds. The compounds are conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.

Подробнее

Номер записи: 63

28-02-2013 дата публикации

Method and kit for quantifying risk predictor

Номер: US20130052139A1

Автор: Sven Lindskog

Принадлежит: DENTOSYSTEM SCANDINAVIA AB

A method and a kit for quantification of at least one predictor promoting at least one multifactorial disease, intended for use in assessment of the risk for developing or progression of the at least one multifactorial disease for a subject are disclosed. The kit comprises a plurality of reservoir units ( 320 ), each reservoir unit ( 320 ) being arranged to releasably retain a skin irritation agent adapted to provoke an unspecific inflammatory response of skin The kit comprises an estimation unit adapted to estimate a quantification of the at least one predictor on basis of an assessment of the at least one predictor performed by a user on basis of an assessment of the degree of severity of the inflammatory response to the skin irritation agent at each of a plurality of skin sites according to a predetermined inflammatory response criteria performed by the user and relative impact of the at least one predictor on the progress of the at least one multifactorial disease.

Подробнее

Номер записи: 64

14-03-2013 дата публикации

Infection activated wound caring compositions and devices

Номер: US20130064772A1

Автор: Gerald F. SWISS, Robert M. Moriarty, Stefan Schwabe

Принадлежит: Indicator Systems International Inc

Provided are wound caring compositions and devices containing a pH-sensitive, preferably acid degradable, components contained in a water-permeable and hydronium ion permeable material. The pH-sensitive component encloses an antibiotic which is released to the wound upon infection by a microorganism at the wound site, and/or encloses a pH indicator. The antibiotic release is triggered by the microorganism's production of CO 2 at the wound site which forms carbonic acid, lowers the pH at the pH sensitive components, and thus results in rupture of the liposome.

Подробнее

Номер записи: 65

21-03-2013 дата публикации

DELIVERY OF AGENTS TO INFLAMED TISSUES USING FOLATE-TARGETED LIPOSOMES

Номер: US20130071321A1

Автор: Low Philip Stewart, Poh Scott

Принадлежит: PURDUE RESEARCH FOUNDATION

The invention described herein pertains to folate-receptor targeted agents comprising therapeutic agents useful for the treatment of inflammatory disease, including folate-receptor targeted liposomes (folate-targeted liposomes) containing entrapped therapeutic agents and folate-receptor targeted dendrimers conjugated to therapeutic agents (folate-targeted dendrimer conjugates), useful for the treatment of inflammatory disease, including auto-immune disease, as well as to folate-targeted liposomes containing entrapped imaging agents and dendrimer conjugates conjugated to imaging agents, for use in the diagnosis and monitoring of treatment in such disease. 1. A folate-receptor targeted agent comprising a therapeutic agent useful for the treatment of inflammatory disease which is a folate-targeted liposomal composition comprising an anti-inflammatory agent as an entrapped agent wherein the lipid bilayer is primarily composed of DSPC/cholesterol with a mol ratio of about 56:40.23-. (canceled)4. The liposomal composition of wherein the lipid bilayer comprises a comprises a folate-targeting conjugate composed of (a) a lipid having a polar head group and a hydrophobic tail claim 1 , (b) a hydrophilic polymer having a first end and a second end claim 1 , said polymer attached at its first end to the head group of the lipid claim 1 , and (c) a folate ligand (Fol) attached to the second end of the polymer claim 1 , and wherein the folate ligand is a folic acid residue or an analog or derivative thereof claim 1 , wherein the hydrophilic polymer of the folate targeting conjugate is a PEG having an average molecular weight of about 200-5000 in which the end groups claim 1 , prior to attachment claim 1 , are independently amino claim 1 , hydroxy claim 1 , thiol or carboxy; and wherein the folate targeting conjugate is present at about 0.01 mol % to about 1 mol % in the lipid bilayer.56-. (canceled)7. The liposomal composition of wherein the lipid bilayer further comprises a ...

Подробнее

Номер записи: 66

21-03-2013 дата публикации

Propynoic Acid Carbamoyl Methyl-Amides and Pharmaceutical Compositions and Methods Based Thereon

Номер: US20130071328A1

Автор: NEAMATI Nouri, PETASIS Nicos A., YAMADA Roppei

Принадлежит: UNIVERSITY OF SOUTHERN CALIFORNIA

This invention discloses a series of novel propynoic acid carbamoyl methyl-amides (PACMAs), methods for synthesizing the PACMAs and pharmaceutical compositions containing the PACMAs. These novel compounds and compositions show cytotoxicity in cancer cells and are useful as lead compounds for anti-cancer drugs or pharmaceutical agents. This invention also discloses treatment methods that uses the PACMAs and pharmaceutical compositions as well as methods for promoting the release and nuclear localization of the transcription factor Nrf2. 4. A compound according to claim 1 , wherein said compound further contains a substituent capable of being used in a biological or medical diagnostic imagining technique to quantify or identify associated biomarker proteins.5. A compound according to claim 3 , wherein said compound further contains a substituent capable of being used in a biological or medical diagnostic imagining technique to quantify or identify associated biomarker proteins.7. A pharmaceutical composition comprising any of the compounds of to and a pharmaceutically acceptable carrier.8. A method for treatment a cancer subject claim 3 , comprising the step of:{'claim-ref': {'@idref': 'CLM-00004', 'claim 4'}, 'administering to a person in need of said treatment method an effective amount of the pharmaceutical composition according to .'}9. A method of claim 8 , where the cancer is: breast cancer claim 8 , ovarian cancer claim 8 , prostate cancer claim 8 , colon cancer claim 8 , brain cancer claim 8 , pancreatic cancer claim 8 , skin cancer claim 8 , lung cancer claim 8 , and multiple myeloma.10. A method for promoting the release and nuclear localization of the transcription factor Nrf2 comprising the step of:{'claim-ref': {'@idref': 'CLM-00004', 'claim 4'}, 'administering an effective amount of the pharmaceutical compositions according to .'}10. A biological or medical diagnostic imaging technique claim 8 , comprising:{'claim-ref': [{'@idref': 'CLM-00004', 'claims 4 ...

Подробнее

Номер записи: 67

21-03-2013 дата публикации

THERANOSTIC DELIVERY SYSTEMS WITH MODIFIED SURFACES

Номер: US20130071329A1

Автор: Ferrari Mauro, Quattrocchi Nicoletta, Tasciotti Ennio

Принадлежит: Board of Regents of the University of Texas System

The present invention pertains to therapeutic compositions and delivery systems comprising at least one microparticle or nanoparticle. In various embodiments, the surface of the microparticle or nanoparticle is modified or functionalized with at least a portion of an isolated cellular membrane, such as an isolated plasma membrane. In addition, the microparticle or nanoparticle contains at least one active agent, such as a therapeutic and/or imaging agent. In additional embodiments, the compositions and delivery systems of the present invention may be used for targeted delivery of an active agent. Also provided are methods of making the therapeutic compositions and delivery systems of the present invention. 1. A composition comprising:at least one microparticle or nanoparticle comprising at least one active agent and a surface,wherein the surface of the at least one microparticle or nanoparticle comprises at least a portion of an isolated cellular membrane.2. The composition of claim 1 , wherein the isolated cellular membrane is an isolated plasma membrane.3. The composition of claim 1 , wherein the isolated cellular membrane is a cellular membrane isolated from a mammalian cell.4. The composition of claim 3 , wherein the isolated cellular membrane is a cellular membrane isolated from a human cell.5. The composition of claim 1 , wherein the isolated cellular membrane is a cellular membrane isolated from an immune cell.6. The composition of claim 5 , wherein the isolated cellular membrane is a cellular membrane isolated from a genetically modified immune cell.7. The composition of claim 5 , wherein the isolated cellular membrane is a cellular membrane isolated from a cell selected from the group consisting of T-cells claim 5 , NK cells claim 5 , monocytes and macrophages.8. The composition of claim 1 , wherein the at least one microparticle or nanoparticle comprises a lipid particle comprising a lipid layer claim 1 ,wherein the lipid layer of said lipid particle ...

Подробнее

Номер записи: 68

21-03-2013 дата публикации

METHODS OF IDENTIFYING AGENTS EFFECTIVE TO TREAT COGNITIVE DECLINE AND DISEASES ASSOCIATED THEREWITH

Номер: US20130071330A1

Автор: Catalano Susan

Принадлежит:

Embodiments described herein are directed to methods of identifying agents effective to treat cognitive decline and diseases associated therewith. Embodiments described herein are also directed to kits for performing methods described herein. Embodiments described are also directed to methods of diagnosis and uses of the same. 1. A method of identifying an agent effective to treat cognitive decline , the method comprising the steps of:contacting a test agent and a processed product of amyloid precursor protein with a composition comprising at least one neuronal cell; andmeasuring a processed product of amyloid precursor protein-mediated effect on the at least one neuronal cell, wherein a test agent that inhibits the processed product of amyloid precursor protein-mediated effect on the cell is thereby identified as an agent that is effective to treat cognitive decline.2. (canceled)3. The method of claim 1 , wherein the processed product of amyloid precursor protein is at least one of an Abeta monomer claim 1 , Abeta oligomer claim 1 , or combinations thereof.4. (canceled)5. The method of claim 1 , wherein the test agent is an agent effective to treat cognitive decline claim 1 , and wherein the test agent does not significantly affect membrane trafficking in the absence of the Abeta monomer claim 1 , Abeta oligomer claim 1 , or combinations thereof.6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. The method of claim 1 , wherein the processed product of amyloid precursor protein is contacted with the composition comprising at least one neuronal cell at a sublethal concentration.11. (canceled)12. The method of claim 1 , wherein the at least one neuronal cell is grown for at least 3 weeks in vitro prior to being contacted with test agent.13. (canceled)14. The method of claim 2 , wherein the effect on membrane trafficking is determined by an MTT assay.15. The method of claim 1 , wherein the step of measuring a processed product of amyloid precursor protein-mediated ...

Подробнее

Номер записи: 69

21-03-2013 дата публикации

NON-DIFFUSIVE BOTULINUM TOXIN CAUSING LOCAL MUSCLE PARALYSIS, AND PURIFICATION METHOD THEREOF

Номер: US20130071331A1

Автор: Chung Yong Hoon, Lee Hyun Sub

Принадлежит: MEDEXGEN INCORPORATED

A method for purifying a non-spreading botulinum toxin that causes local muscle paralysis and a non-spreading botulinum toxin obtained thereby includes the steps of: subjecting a purified botulinum toxin type A product to ion-exchange chromatography using a controlled pH of buffer, concentration of sodium chloride (NaCl), thereby separating the botulinum toxin type A product into subfractions; and collecting a subfraction having an A260/A280 value in a specific range from the separated subfractions. 13-. (canceled)4. A method for purifying a non-spreading botulinum toxin , comprising the steps of:separating the botulinum toxin type A product into subfractions by conducting ion-exchange chromatography using pH 4.5-6.5 buffer and 0.02-0.2 M of sodium chloride (NaCl); andcollecting a non-spreading botulinum toxin subfraction, which has an A260/A280 value of 0.4-0.6, from the said separated subfractions.5. A non-spreading botulinum toxin preparation , which is purified by the above method comprises , Zn , Fe and Mg ion concentrations at least 150 , 80 , and 140 ppb per 100 U/ml , respectively.62. A method for determining a non-spreading botulinum toxin , comprising injection the non-spreading botulinum toxin preparation of claim into the either left or right hind limb calf muscle of mouse (4-6 wk old , weighing 18-22 g) in an amount equivalent to 1.5-3 times the LDof the toxin in the volume ranges of 20-50 μL; and determining whether the hind limb muscles injected and respiratory muscles of the mouse were paralyzed and whether the mouse died.7. The method of claim 6 , wherein the non-spreading botulinum toxin preparation shows a survival rate at least 80% at 96 hours after injection of 2 U toxin preparation in the volume 50 μL either left or right hind limb calf muscle of mouse (4-6 wk old claim 6 , weighing 18-22 g). The present invention relates to a method for purifying a non-spreading botulinum toxin that causes local muscle paralysis and a non-spreading botulinum ...

Подробнее

Номер записи: 70

28-03-2013 дата публикации

Method for Selecting Bacteria with Anti-Oxidant Action

Номер: US20130078187A1

Автор: Bourdet-Sicard Raphaelle, Chambaud Isabelle, Degivry Marie-Christine, Genoves Martinez Salvador, Gonzalez Martinez Nuria, Grompone Gianfranco, Legrain-Raspaud Sophie, Martorell Guerola Patricia, Ramon Vidal Daniel

Принадлежит:

The present invention relates to a method using for screening of food grade bacteria which have a protective effect against oxidative stress. 1. A method for selecting food grade bacteria with anti-oxidative properties comprising:{'i': 'Caenorhabditis elegans', 'a. a step of synchronizing the growth of worms;'}{'i': 'C. elegans', 'b. a step of feeding the worms on the food grade bacteria to be tested;'}{'i': 'C. elegans', 'c. a step of incubating the worms in the presence of oxidative stress;'}{'i': 'C. elegans', 'd. a step of determining the viability of said worms which were incubated in the presence of oxidative stress; and'}{'i': 'C. elegans', 'e. a step of selecting the food grade bacteria which provide the highest survival of said worms in the presence of oxidative stress.'}2. The method according to claim 1 , characterized in that:{'i': 'C. elegans', 'step c further comprises a step of incubating worms in the absence of oxidative stress as a control, and in that'}{'i': C. elegans', 'C. elegans, 'step d further comprises a step of comparing the viability of said worms which were incubated in the presence of oxidative stress to the viability of said worms which were incubated in the absence of oxidative stress.'}3C. elegansC. elegans. The method according to claim 1 , characterized in that said worms are mutant strains BA17 fem-1(hc17).4C. elegans. The method according to claim 1 , characterized in that said are grown in the wells of a microtiter plate.5C. elegans. The method according to claim 1 , characterized in that the are grown on agar plates.6Escherichia coliE. coli. The method according to claim 1 , characterized in that a group of worms receives an feeding claim 1 , more preferably OP50 claim 1 , as a control.7. The method according to claim 1 , characterized in that the worms are grown and incubated in the presence of an antibiotic.8. The method according to claim 1 , characterized in that said antibiotic is kanamycin claim 1 , preferably kanamycin at ...

Подробнее

Номер записи: 71

28-03-2013 дата публикации

ACTIVATABLE CELL PENETRATING PEPTIDES WITH QUENCHED FLUOROPHORES

Номер: US20130078188A1

Автор: Jiang Tao, Savariar Elamprakash N., Tsien Roger Y.

Принадлежит: The Regents of the University of California

The invention provides compositions useful as molecular probes. In particular, the invention provides activatable cell penetrating peptides comprising a fluorescence donor and a fluorescence acceptor. Exemplary fluorescence donors and fluorescence acceptors include compounds derived from cyanine. Also provided are ratiometric, multispectral, and excitation lifetime imaging methods for detecting the molecular probes provided herein. 1. A compound comprising the structure:{'br': None, 'PAP-CL-PCP'} PAP is a polyanionic peptide comprising a fluorescence acceptor;', 'CL is a first linker, wherein the first linker is cleavable; and', 'PCP is a polycationic peptide comprising a fluorescence donor comprising a cyanine., 'wherein2. The compound of claim 1 , further comprising a targeting moiety.3. The compound of claim 2 , wherein the targeting moiety is attached via a second linker.4. The compound of claim 2 , wherein the targeting moiety is a cyclo-RGDfK peptide.5. The compound of claim 3 , wherein the second linker is attached to a first derivatized amino acid in the polyanionic peptide.6. The compound of claim 3 , wherein the second linker comprises poly(ethyleneglycol).7. The compound of claim 1 , wherein the fluorescence donor is attached to a second derivatized amino acid in the polycationic peptide.8. The compound of claim 1 , wherein the polyanionic peptide comprises nine consecutive glutamate residues.9. The compound of claim 1 , wherein the polycationic peptide comprises nine consecutive arginine residues.10. The compound compound of claim 5 , wherein the first derivatized amino acid is derivatized cysteine.11. The compound of claim 7 , wherein the second derivatized amino acid is derivatized cysteine.12. The compound of claim 1 , wherein the cleavable linker is an MMP-9 claim 1 , MMP-2 claim 1 , elastase claim 1 , or thrombin substrate.13. The compound of claim 1 , wherein the first linker comprises a peptide having an amino acid sequence selected from the group ...

Подробнее

Номер записи: 72

28-03-2013 дата публикации

Formation and uses of europium complexes

Номер: US20130078189A1

Автор: Jeremiah Moore, Joel Garcia, Matthew J. Allen, Nipuni Dhanesha H. Gamage

Принадлежит: WAYNE STATE UNIVERSITY

The present invention provides a method of forming an oxidatively-stable aqueous Eu(II) complex by synthesizing ligands that coordinate to large, soft, electron rich metals like Eu(II). The invention also provides an oxidatively stable aqueous Eu(II) complex. The complex can be used for a variety of purposes some of which include, but are not limited to, in paramagnetic chemical exchange saturation transfer, as a medical diagnostic, as a semiconductor, and for use in forming materials.

Подробнее

Номер записи: 73

04-04-2013 дата публикации

METHOD AND SYSTEM FOR QUANTITATIVE RENAL ASSESSMENT

Номер: US20130084246A1

Автор: Jackson Hollie, Moats Rex, Sharma Priyank, Tang Yang

Принадлежит: CHILDREN'S HOSPITAL LOS ANGELES

Method and system embodiments of the present invention employ computational analysis tools running on one or more computer systems to quantitatively analyze MRI data from patients in order to both assess various functional parameters and characteristics of a patient's kidney, as well as to provide an electronic display device interconnected with the one or more computer systems, and accessible visualization of the quantitative assessment to facilitate diagnosis of various types of kidney abnormalities and pathologies. 1. A quantitative-organ-assessment system comprising:(a) a computer system;(b) a time series of MRI images obtained in the absence and presence of an MRI contrast-enhancing substance, stored as a dataset within the computer system, wherein the dataset comprises intensities associated with voxels at each time point in the time series of MRI images; and (i) compressing the dataset to fewer dimensions,', '(ii) partitioning voxels within the dataset into clusters, each cluster containing voxels with similar time-intensity curves, and', '(iii) computing functional characteristics and parameters of the organ from aggregate intensity-versus-time characteristics of the voxels within the clusters., '(c) a quantitative-organ-assessment component, executing on one or more processors of the computer system, which generates an assessment of the organ imaged in the time series of MRI images by2. A quantitative-renal-assessment system comprising:(a) a computer system;(b) a time series of MRI images obtained in the absence and presence of an MRI contrast-enhancing substance, stored as a dataset within the computer system, wherein the dataset comprises intensities associated with voxels at each time point in the time series of MRI images; and (i) compressing the dataset to fewer dimensions,', '(ii) partitioning voxels within the dataset into clusters, each cluster containing voxels with similar time-intensity curves, and', '(iii) computing functional characteristics ...

Подробнее

Номер записи: 74

04-04-2013 дата публикации

COMPOSITIONS AND METHODS TO PREVENT CANCER WITH CUPREDOXINS

Номер: US20130084247A1

Автор: Beattie Craig, Chakrabarty Ananda, Das Gupta Tapas, Yamada Tohru

Принадлежит: The Board of Trustees of the University of Illinois

The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The cargo compound may be a nucleic acid and specifically a DNA, RNA or anti-sense. The invention further discloses methods for treating cancer and diagnosing cancer. 1. An isolated peptide that is a variant , derivative or structural equivalent of a cupredoxin; and that can inhibit the development of premalignant lesions in mammalian tissue.2. The isolated peptide of claim 1 , wherein the cupredoxin is selected from the group consisting of azurin claim 1 , pseudoazurin claim 1 , plastocyanin claim 1 , rusticyanin claim 1 , Laz claim 1 , auracyanin claim 1 , stellacyanin and cucumber basic protein.3. The isolated peptide of claim 2 , wherein the cupredoxin is azurin.4Pseudomonas aeruginosa, Alcaligenes faecalis, Achromobacter xylosoxidan, Bordetella bronchiseptica, MethylomonasNeisseria meningitidis, Neisseria gonorrhea, Pseudomonas fluorescens, Pseudomonas chlororaphis, Xylella fastidiosaVibrio parahaemolyticus.. The isolated peptide of claim 1 , wherein the cupredoxin is from an organism selected from the group consisting of sp. claim 1 , and5Pseudomonas aeruginosa.. The isolated peptide of claim 4 , that is from6. The isolated peptide of claim 1 , which is part of a peptide selected from the group consisting of SEQ ID NOS: 1 claim 1 , 3-19.7. The isolated peptide of claim 1 , to which a sequence selected from the group consisting of SEQ ID NOS: 1 claim 1 , 3-19 has at least 80% amino acid sequence identity.8. The isolated peptide of claim 1 , which is a truncation of the cupredoxin.9. The isolated peptide of claim 8 , wherein the peptide is more than about 10 residues and not more than about 100 residues.10Pseudomonas aeruginosaPseudomonas aeruginosaPseudomonas aeruginosa. The isolated peptide of claim 8 , wherein the peptide comprises a ...

Подробнее

Номер записи: 75

04-04-2013 дата публикации

STABILIZED, BIOCOMPATIBLE GOLD NANOPARTICLES

Номер: US20130084248A1

Автор: Kannan Raghuraman, Katti Kativa K., Katti Kattesh V., Nune Satish Kumar

Принадлежит: The Curators of the University of Missouri

The invention provides stabilized, biocompatible gold nanoparticles that are stabilized with material from polyphenols- or flavanoids-rich plant material or reactive phytochemical components of the plant material. The gold nanoparticles of the invention can be fabricated with an environmentally friendly method for making biocompatible stabilized gold nanoparticles. In preferred embodiments, the coating consists of material from polyphenols- or flavanoids-rich plant material or reactive phytochemical components of the plant material. 1. Gold nanoparticles stabilized with a material coating of material from polyphenols- or flavanoids-rich plant material or reactive phytochemical components of the plant material.2. The gold nanoparticles of claim 1 , wherein the plant material comprises black tea.3. The gold nanoparticles of claim 1 , wherein the plant material comprises turmeric or its component curcumin.4. The gold nanoparticles of claim 1 , wherein the plant material comprises cinnamon.5. The gold nanoparticles of claim 1 , in an aqueous solution having a physiological pH.6. A method of sensing comprising introducing stabilized gold nanoparticles of into a human or animal subject and conducting gold nanoparticle enhanced imaging.7. A method of therapy comprising introducing stabilized gold nanoparticles of into a human or animal subject and conducting gold nanoparticle enhanced therapy.8. The gold nanoparticles of claim 1 , wherein the coating consists of polyphenols- or flavanoids-rich plant material.9. The gold nanoparticles of claim 1 , consisting of nanoparticles that are homogenous with a common diameter.10. The gold nanoparticles of claim 9 , wherein the common diameter is 13±5 nm. The application is a divisional application of and claims priority under 35 U.S.C. §120 from prior application Ser. No. 12/283,935, which was filed on Sep. 17, 2008, now Pat. No. ______, which claimed priority under 35 U.S.C. §119 from prior provisional application Ser. No. 60/994, ...

Подробнее

Номер записи: 76

04-04-2013 дата публикации

Poly(beta malic acid) with pendant leu-leu-leu tripeptide for effective cytoplasmic drug delivery

Номер: US20130084261A1

Автор: Eggehard Holler, Hui Ding, Julia Y. Ljubimova, Keith L. Black

Принадлежит: Cedars Sinai Medical Center

The invention relates to the use of Polycefin-LLL nanoconjugate as a means of cytoplasmic delivery of drugs. In one embodiment, the present invention provides a drug delivery molecule, comprising a polymerized carboxylic acid molecular scaffold covalently linked to L-leucylleucylleucine. In another embodiment, the Polycefin-LLL includes drug antisense morpholino oligos, targeting antibodies, and a pH-sensitive endosome escape unit. In addition, the drug could be siRNA, microRNA, and aptamer.

Подробнее

Номер записи: 77

11-04-2013 дата публикации

SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE

Номер: US20130089505A1

Автор: Adams H. Clark, Friedman Peter, Kerber Charles W.

Принадлежит: Valor Medical, Inc.

Alkyl cyanoacrylate compositions and methods for making those compositions, utilizing high purity monomeric starting materials, formed into more viscous oligomers, and combined with a plasticizer and inhibitor to provide a single-container, storage stable medical cyanoacrylate. 1. A medical grade composition suitable for application to or in the human body , comprising a mixture of:(a) a polymerizable alkyl cyanoacrylate oligomer, wherein said polymerizable alkyl cyanoacrylate oligomer has a viscosity of from 10 centipoise to 30 centipoise;(b) at least one polymerization inhibitor;(c) a contrast agent; and(d) a plasticizer,wherein said composition is sealed in a single container and is stable for more than one month at room temperature, and is adapted to polymerize in vivo.2. The composition of claim 1 , wherein the polymerizable alkyl cyanoacrylate oligomer is selected from the group consisting of 2-hexyl cyanoacrylate oligomer claim 1 , n-hexyl cyanoacrylate oligomer claim 1 , pentyl cyanoacrylate oligomer claim 1 , heptyl cyanoacrylate oligomer claim 1 , and octyl cyanoacrylate oligomer.3. The composition of claim 1 , wherein the polymerizable alkyl cyanoacrylate oligomer is n-hexyl cyanoacrylate oligomer.4. The composition of claim 1 , wherein the inhibitor is selected from the group consisting of 4-methoxyphenol claim 1 , 2 claim 1 ,6-di-tert-butyl-4-methylphenol claim 1 , hydroquinone claim 1 , phosphoric acid claim 1 , sulfur dioxide (SO) claim 1 , and any combination thereof.5. The composition of claim 4 , wherein the inhibitor is a mixture of 4-methoxyphenol claim 4 , 2 claim 4 ,6-di-tert-butyl-4-methylphenol claim 4 , and sulfur dioxide.6. The composition of claim 1 , wherein the plasticizer is tri-n-butyl O-acetylcitrate.7. The composition of claim 1 , wherein the contrast agent is selected from the group consisting of gold claim 1 , platinum claim 1 , tantalum claim 1 , titanium claim 1 , tungsten claim 1 , barium sulfate claim 1 , and combinations ...

Подробнее

Номер записи: 78

11-04-2013 дата публикации

Artery- and vein-specific proteins and uses therefor

Номер: US20130091591A1

Автор: David J. Anderson, Hai U. Wang, Zhoufeng Chen

Принадлежит: California Institute of Technology CalTech

Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example.

Подробнее

Номер записи: 79

18-04-2013 дата публикации

METHODS AND COMPOSITIONS FOR DIAGNOSIS OF IGA-AND IGM-MEDIATED KIDNEY DISEASES

Номер: US20130095036A1

Автор: Plaut Andrew G., Qiu Jiazhou, Qiu Robert

Принадлежит:

The present invention features noninvasive methods for diagnosing IgA or IgM kidney disorders, such as IgA nephropathy, Henoch-Schönlein purpura, and IgM nephropathy, in a mammal. The invention also features compositions and kits useful in diagnosing these disorders. 1. A method for diagnosing an IgA or IgM kidney disease in a mammal , said method comprising:(a) administering to said mammal a compound which specifically binds IgA or IgM; and(b) detecting said compound in the kidney of said mammal, wherein an increase in the amount of said compound in said kidney of said mammal relative to the amount in the kidney of a mammal without said kidney disease is diagnostic of said IgA or IgM kidney disease in said mammal.23-. (canceled)4. The method of claim 1 , wherein said compound comprises a peptide.5. The method of claim 4 , wherein said peptide is selected from the group consisting of human FcαR1 (SEQ ID NO:2) claim 4 , human Fcα/μ receptor (SEQ ID NO:6) claim 4 , polymeric Ig receptor (SEQ ID NO:7) claim 4 , Sir22 (SEQ ID NO:3) claim 4 , streptococcal IgA-binding peptide (Sap; SEQ ID NO:4) claim 4 , a modified Z-domain protein (SEQ ID NO: 12) claim 4 , and YDWIPSSAW (SEQ ID NO:9) claim 4 , or an IgA- or IgM-binding fragment thereof.6. (canceled)7. The method of claim 1 , wherein said compound comprises an antibody claim 1 , or an IgA- or IgM-binding fragment thereof.816-. (canceled)17. The method of claim 1 , wherein said compound is linked to a paramagnetic substance.18. The method of claim 17 , wherein said paramagnetic substance is gadolinium.1920-. (canceled)21. The method of claim 1 , wherein said compound further comprises a galactose and a first member of a binding pair.22. The method of claim 21 , wherein said first member of a binding pair is streptavidin.23. The method of claim 21 , wherein said administration further comprises administration of galactose-Ficoll.24. The method of claim 21 , wherein said detection is performed by administering to said ...

Подробнее

Номер записи: 80

18-04-2013 дата публикации

NUCLEIC ACID-MEDIATED SHAPE CONTROL OF NANOPARTICLES

Номер: US20130095039A1

Автор: Lu Yi, WANG Zidong

Принадлежит: The Board of Trustees of the University of Illinois

Embodiments of a method to use nucleic acid oligomer sequences for modulating the shape of nanoparticles are disclosed, as well as nanoparticles and methods of using the nanoparticles. Systematic variations of the nucleic acid sequences offer mechanistic insights into the morphology control. A plurality of nucleic acid oligomers is adsorbed onto a metal nanoseed to provide an oligomer-functionalized nanoparticle. Additional metal is deposited onto the oligomer-functionalized nanoparticle to produce a shaped nanoparticle having a morphology based at least in part on the nanoseed morphology and the oligomer's sequence composition. Embodiments of methods for using the shaped nanoparticles also are disclosed. 1. A method for making a shaped nanoparticle , comprising:providing a metal nanoseed;selecting a nucleic acid oligomer having an oligomer sequence composition comprising at least two unique sequence segments, each sequence segment having a length of at least five nucleobases selected from the group consisting of A, C, G, T, U, and modified nucleobases;adsorbing a plurality of the nucleic acid oligomers onto the metal nanoseed to produce an oligomer-functionalized nanoseed; anddepositing metal onto the oligomer-functionalized nanoseed to make a shaped nanoparticle, wherein the shaped nanoparticle has a morphology based at least in part on the oligomer sequence composition.2. The method of claim 1 , further comprising determining the morphology of the shaped nanoparticle claim 1 , wherein the morphology comprises shape claim 1 , surface characteristics claim 1 , or a combination thereof.3. The method of claim 2 , further comprising:providing a subsequent metal nanoseed having a morphology substantially similar to the metal nanoseed;selecting a subsequent nucleic acid oligomer having a subsequent oligomer sequence composition comprising at least two subsequent sequence segments, each subsequent sequence segment comprising nucleobases selected from the group consisting ...

Подробнее

Номер записи: 81

18-04-2013 дата публикации

DYE COMPOSITIONS AND DYE SYNTHESES

Номер: US20130095040A1

Автор: Mokkapati Umamaheshwar P.

Принадлежит: GE HEALTHCARE AS

The present invention relates to sulfonated unsymmetrical pentamethine optical dye compositions, especially dyes suitable for biological applications in vitro, and for in vivo imaging. Improved dye compositions and intermediates are provided, which enable the suppression of undesirable newly-identified impurities. Also provided is the use of the improved dye compositions in the preparation of conjugates with biological targeting molecules. 114-. (canceled)16. The composition of claim 15 , where Ris H.17. The composition of claim 15 , where Rto Rare independently CHor an Rgroup.19. The composition of claim 15 , which further comprises sulfonate ester derivatives of Formula A claim 15 , Bor C claim 15 , which correspond to the dyes of Formula A claim 15 , B or C respectively wherein at least one of Rand Ris —SO—OR claim 15 , where Ris Calkyl or an Rgroup; Ris an Ror Rgroup; Ris Csulfoalkyl; and Ris Ccarboxyalkyl; such that the molar ratio of A: (A+B+C) is at least 92:1.24. A method comprising reaction of the composition of with an alkylating agent of formula R—X claim 23 , where Ris an Rgroup; Ris Calkyl or an Rgroup; Ris an Ror Rgroup; Ris Csulfoalkyl; Ris Ccarboxyalkyl; and X is a leaving group.26. A pharmaceutical composition which comprises the composition of claim 15 , in a biocompatible carrier medium claim 15 , in sterile form suitable for mammalian administration. The present invention relates to the field of sulfonated unsymmetrical pentamethine optical dyes, especially dyes suitable for biological applications in vitro, and for in vivo imaging. Improved dye compositions and intermediates are provided, which enable the suppression of undesirable newly-identified impurities.The sulfonation of dyes by the introduction of sulfonate (—SOH or —SO) substituents is an established method of increasing the water solubility of the dye.WO 2005/044923 and US 2007/0203343 A1 disclose the synthesis of new class of sulfonated pentamethine and heptamethine cyanine dyes ...

Подробнее

Номер записи: 82

18-04-2013 дата публикации

Skin Profiling and Its Use in Testing Cosmetics

Номер: US20130095041A1

Автор: BARKER STEPHEN GEORGE EDWARD, Hopper Colin

Принадлежит: AME HEALTH LTD

A method of profiling skin comprises comparing the rugosity and/or the length of rete ridges beneath the skin relative to a length of skin and optionally also the relative thicknesses (or volumes) of the dermis and the epidermis. The method allows for determination of the ability of a cosmetic formulation to hydrate or “plump” skin. 1. A method of profiling skin , which comprises comparing the rugosity and/or the length of rete ridges beneath the skin relative to a length of skin.2. The method according to claim 1 , which additionally comprises comparing the thickness of the epidermis and the dermis.3. A method for determining the effectiveness of a cosmetic preparation on skin claim 1 , which comprises determining the thickness of the dermis before and after treatment with the cosmetic preparation claim 1 , wherein increased thickness of the dermis after the treatment is indicative of the ability of the cosmetic preparation to hydrate the skin.4. A method for determining the effectiveness of a cosmetic preparation on skin claim 1 , which comprises determining the rugosity and/or length of rete ridges before and after treatment with the cosmetic preparation claim 1 , wherein reduced rugosity and/or reduced length of the rete ridges is indicative of the ability of the cosmetic preparation to hydrate the skin.5. (canceled)6. The method claim 1 , according to claim 1 , wherein a degree of hydration of the skin is determined.7. The method claim 3 , according to claim 3 , which further comprises determining the rugosity and/or length of rete ridges before and after treatment with the cosmetic preparation claim 3 , wherein reduced rugosity and/or reduced length of the rete ridges is indicative of the ability of the cosmetic preparation to hydrate the skin. This invention relates to skin testing and, more particularly, to a method of testing the effectiveness of cosmetics.Women in particular, although not exclusively, are concerned about the appearance of wrinkles and the ...

Подробнее

Номер записи: 83

18-04-2013 дата публикации

Treatment of immune disease by mucosal delivery of antigens using genetically modified lactobacillus

Номер: US20130095129A1

Автор: Pieter Rottiers, Veerle Snoeck

Принадлежит: ACTOGENIX NV

The present invention relates to the treatment of autoimmune and allergic diseases by mucosal delivery by micro-organism, in particular Lactococcus lactis , of secreted immunodominant antigens.

Подробнее

Номер записи: 84

18-04-2013 дата публикации

Compositions and methods for enhancing drug delivery across and into ocular tissues

Номер: US20130096069A1

Автор: Jonathan B. Rothbard, Lalitha V.S. Sista, P. Leo Mcgrane, Paul A. Wender, Thorsten A. Kirschberg

Принадлежит: CellGate Inc

This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including into and across ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.

Подробнее

Номер записи: 85

18-04-2013 дата публикации

Method of forming hemostatic products

Номер: US20130096479A1

Автор: Curtis E. Olson, Philip A. Messina

Принадлежит: St Teresa Medical Inc

A hemostatic product having a plurality of hemostatic layers. Each of the hemostatic layers includes a dextran support and at least one hemostatic agent, which is selected from the group consisting of thrombin and fibrinogen. The hemostatic layers are arranged in a stacked configuration.

Подробнее

Номер записи: 86

25-04-2013 дата публикации

COMPOSITIONS COMPRISING NUCLEIC ACID APTAMERS

Номер: US20130101506A1

Автор: Smith Cassandra L.

Принадлежит:

Disclosed herein are aptamers that comprise a nucleic acid sequence that has a specific affinity for a target. These aptamers can be used as delivery vehicles to deliver specific agents to particular sites. Alternatively, targeted aptamers can also be used with detection techniques to determine the presence of absence of specific targets in heterogeneous backgrounds. 1. An aptamer that binds to CEA , wherein the aptamer comprises a consensus nucleic , acid sequence selected from the group consisting of SEQ ID NOs: 3 , 4 , 5 , 6 , 7 , 8 , and 9.2. The aptamer of claim 1 , wherein the aptamer comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 10 claim 1 , 11 claim 1 , 12 claim 1 , 13 claim 1 , 16 claim 1 , 17 claim 1 , 18 claim 1 , 19 claim 1 , 20 claim 1 , 21 claim 1 , 22 claim 1 , 23 claim 1 , 24 claim 1 , 25 claim 1 , 26 claim 1 , 27 claim 1 , 28 claim 1 , 29 claim 1 , 30 claim 1 , 31 claim 1 , 32 claim 1 , 33 claim 1 , 34 claim 1 , 35 claim 1 , 36 claim 1 , and 37.3. The aptamer of claim 1 , having a dissociation constant of about 4 nM to about 20 nM.4. The aptamer of claim 1 , wherein the aptamer comprises single-stranded DNA claim 1 , RNA or PNA.5. The aptamer of claim 1 , wherein the aptamer comprises natural or non-naturally occurring bases.6. The aptamer of claim 1 , wherein the aptamer comprises a chemical backbone selected from the group consisting of a phosphodiester claim 1 , a phosphorothioate claim 1 , a methylene phosphorothioate claim 1 , a peptide and other chemical modifications.7. The aptamer of claim 5 , wherein the non-naturally occurring bases are selected from the group consisting of methylinosine claim 5 , dihydrouridine claim 5 , methyl guanosine and thiouridine.8. A method of identifying claim 1 , detecting claim 1 , or imaging cells or tissues expressing CEA claim 1 , the method comprising administering to a subject the aptamer of .9. The method of claim 8 , wherein the aptamer comprises a nucleic acid ...

Подробнее

Номер записи: 87

25-04-2013 дата публикации

IN VIVO IMAGING OF ENZYMATIC ACTIVITY

Номер: US20130101511A1

Автор: Ansaldi Daniel, Francis Kevin P., Singh Rajendra, Zhang Ning

Принадлежит:

Compositions and methods are described for detecting enzyme activity in a live organism (e.g., animal) are provided. 1. A composition comprising a chemiluminescent enzymatic probe and a near-infrared (NIR) nanop article.2. The composition of claim 1 , wherein the chemiluminescent enzymatic probe comprises luminol.3. The composition of claim 1 , wherein the NIR nanoparticle further comprises a targeting moiety.4. The composition of claim 3 , wherein the targeting moiety is selected from the group consisting of an antibody claim 3 , an antibody fragment claim 3 , a small molecule claim 3 , an apatmer and a polypeptide.5. A method of monitoring enzymatic activity in a live animal claim 3 , the method comprising:administering a chemiluminescent enzymatic probe to the animal;administering a near-infrared (NIR) nanoparticle to the animal, wherein the nanoparticle emits light upon exposure to the chemiluminescence emitted from the chemiluminescent enzymatic probe;detecting the light emitted from the light nanoparticle, thereby monitoring enzymatic activity in the live animal.6. The method of wherein the chemiluminescent enzymatic probe comprises luminol.7. The method of claim 6 , wherein ROS activity is monitored.8. The method of claim 6 , wherein a cancer is detected.9. The method of claim 6 , wherein the enzymatic activity is indicative of an inflammatory response.10. The method of claim 9 , wherein the inflammatory response is in the lungs.11. The method of claim 6 , wherein the enzymatic activity is indicative of the present of a tumor or tumor metastases.12. A method of detecting a cancer in a live animal claim 6 , the method comprising:administering a chemiluminescent enzymatic probe to the animal;administering a near-infrared (NIR) nanoparticle to the animal, wherein the nanoparticle emits light upon exposure to the chemiluminescence emitted from the chemiluminescent enzymatic probe;detecting the light emitted from the NIR nanoparticle, thereby monitoring the cancer ...

Подробнее

Номер записи: 88

25-04-2013 дата публикации

CROSSLINKED POLYNUCLEOTIDE STRUCTURE

Номер: US20130101512A1

Автор: Cutler Joshua I., Giljohann David A., Mirkin Chad A., Thaxton C. Shad

Принадлежит:

The present invention provides structures formed from crosslinked polynucleotides, where a subset of the polynucleotides binds to a target under physiological conditions, where the signal group detectably changes upon binding. 1. A structure formed from crosslinked polynucleotides , comprising:a plurality of crosslinkable polynucleotides that are crosslinked; where a subset of the crosslinkable polynucleotides are binding polynucleotides that are sufficiently complementary to a target to allow them to hybridize under physiological conditions;a plurality of signaling moieties hybridized to at least some of the binding polynucleotides in the structure, where each signaling moiety comprise either a quencher or a signal group attached to a signal polynucleotide which is sufficiently complementary to the binding polynucleotide to allow it to hybridize under physiological conditions,when the signaling moiety comprises the quencher, then the signal group is bound to the structure, or when the signaling moiety comprises the signal group, then the quencher is bound to the structure;where lack of hybridization leads to a detectably change in the signal.2. The structure of claim 1 , which is metal free.3. The structure of claim 1 , which is hollow.4. The structure of claim 1 , further comprising a spacer claim 1 , wherein the crosslinkable polynucleotides are crosslinked through the spacer.5. The structure of claim 1 , where the quencher is bound to the structure.6. The structure of claim 1 , where the signal is bound to the structure.7. The structure of claim 1 , wherein the crosslinkable polynucleotides are crosslinked via amine claim 1 , amide claim 1 , alcohol claim 1 , ester claim 1 , aldehyde claim 1 , ketone claim 1 , thiol claim 1 , disulfide claim 1 , carboxylic acid claim 1 , phenol claim 1 , imidazole claim 1 , hydrazine claim 1 , hydrazone claim 1 , azide claim 1 , or alkyne groups.8. The structure of claim 7 , wherein the crosslinkable polynucleotides are ...

Подробнее

Номер записи: 89

25-04-2013 дата публикации

METHOD OF USING NEAR INFRARED FLUORESCENT DYES FOR IMAGING AND TARGETING CANCERS

Номер: US20130101513A1

Автор: Chung Leland W.K., Wang Ruoxiang, Yang Xiaojian, Zhau Haiyen E.

Принадлежит:

The present invention describes methods of identifying, detecting, imaging, isolating and locating cancer cells in a subject. The method invokes the use of near-infrared (NIR) organic carbocyanine dyes, particularly, near infrared heptamethine cyanine dyes and the detection of the fluorescence of these NIR dyes. The uptake of these dyes by cancer cells and not by normal cells, as well as their high intensity, among other things, allow for the detection of cancerous cells in a subject and facilitate their subsequent isolation. Further, detection of many tumor types and tumor cell populations under cell culture and in vivo conditions are described. 1. A method , comprising:providing a biological sample from a subject;contacting the biological sample with a composition comprising a near-infrared (NIR) organic carbocyanine dye to form a mixture; andanalyzing the mixture to identify, detect, locate, isolate and/or characterize a possible cancer cell or tumor in the biological sample.2. The method of claim 1 , wherein the biological sample is selected from the group consisting of tissue claim 1 , tumor tissue claim 1 , cancer tissue claim 1 , cell claim 1 , tumor cell claim 1 , cancer cell claim 1 , body fluid claim 1 , whole blood claim 1 , plasma claim 1 , stool claim 1 , intestinal fluid or aspirate claim 1 , stomach fluid or aspirate claim 1 , serum claim 1 , cerebral spinal fluid (CSF) claim 1 , urine claim 1 , sweat claim 1 , saliva claim 1 , tears claim 1 , pulmonary secretion claim 1 , breast aspirate claim 1 , breast milk claim 1 , prostate fluid claim 1 , seminal fluid claim 1 , cervical scraping claim 1 , bone marrow aspirate claim 1 , amniotic fluid claim 1 , intraocular fluid claim 1 , mucous claim 1 , moisture in breath.3. The method of claim 1 , wherein the method identifies or detects the presence of a cancer cell or a tumor in the biological sample when a presence of an increased NIR fluorescent signal claim 1 , relative to a background staining intensity ...

Подробнее

Номер записи: 90

25-04-2013 дата публикации

Compositions and methods for treating nephropathy

Номер: US20130101514A1

Автор: Daniel Joseph Cushing

Принадлежит: Complexa Inc

Activated fatty acids, pharmaceutical composition compositions including activated fatty acids, methods for using activated fatty acids to treat nephropathy, and methods for preparing activated fatty acids are provided herein.

Подробнее

Номер записи: 91

25-04-2013 дата публикации

METHOD OF SELECTING ANTIOXIDANTS FOR USE IN TOPICALLY APPLIED COMPOSITIONS

Номер: US20130101515A1

Автор: Beasley Donathan G., Meyer Thomas A.

Принадлежит:

The invention provides antioxidant-containing compositions and methods for confirming antioxidant activity of a composition formulated for topical application to skin. The invention also provides methods for testing a composition for the ability to inhibit both ultraviolet radiation-induced lipid peroxidation on skin and ultraviolet radiation-induced reactive oxygen species formation in the stratum corneum, as well as compositions and methods for treating and preventing photodamage to skin. 136-. (canceled)37. A method for confirming antioxidant activity of a composition formulated for topical application to skin , wherein the method comprises testing the composition for ability to inhibit both ultraviolet radiation-induced lipid peroxidation on skin and ultraviolet radiation-induced reactive oxygen species formation in the epidermis.38. A method for screening compounds for antioxidant behavior in a composition to be topically applied to skin , wherein the screening method comprises determining the compound's ability to inhibit both ultraviolet radiation-induced skin lipid hydroperoxide formation and ultraviolet radiation-induced reactive oxygen species formation in the epidermis.39. The method of claim 38 , wherein determining inhibition of ultraviolet radiation-induced reactive oxygen species formation in the epidermis comprises imaging skin tissue using two-photon fluorescence intensity imaging.40. The method of claim 38 , wherein determining inhibition of UVR-induced skin lipid hydroperoxide formation comprises determining percent lipid hydroperoxide inhibition of the compound in comparison to placebo.41. The method of claim 40 , comprising the steps of applying to distinct areas of skin of a subject an antioxidant containing composition and a placebo composition to produce an antioxidant skin site containing antioxidant and skin lipids and a placebo skin site containing placebo and skin lipids; applying a strip to the antioxidant skin site and the placebo skin ...

Подробнее

Номер записи: 92

25-04-2013 дата публикации

METHOD AND APPARATUS FOR KIDNEY FUNCTION ANALYSIS

Номер: US20130101518A1

Автор: MOLITORIS Bruce A., SANDOVAL Ruben M., YU Weiming

Принадлежит: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION

A method and apparatus for determining physiological data related to an animal, such as kidney diagnostics data, is provided. The method includes injecting a mixture of a first and a second molecule into an animal (e.g., a human patient), determining a molecular ratio of the molecules, and determining the physiological data based on the molecular ratio. The apparatus includes a number of finger receiving apertures, a light generation circuit, a light detection circuit, a pulse counting circuit, and a user interface. 145.-. (canceled)46. A method for determining the metabolic rate of a test molecule in an animal , the method comprising the steps of:a) administering a first molecule and a second molecule to the animal, wherein the second molecule is cleared from the animal at a rate lower than the rate at which the first molecule is cleared from the animal;{'sub': B', 'A', 'B', 'A', '(t)', 'B', 'A, 'claim-text': {'br': None, 'i': R', '/R', '=I', '/I, 'sub': B', 'A', 'B', 'A, ','}, 'b) determining the molecular ratio (R/R) of the first molecule to the second molecule in the animal over a period of time to obtain a time series of molecular ratios (R/R), the molecular ratio (R/R) being determined using the following equation{'sub': B', 'A, 'wherein Iis the level of the first molecule in the animal and Iis the level of the second molecule in the animal;'}{'sub': 1', 'B', 'A', '(t), 'claim-text': {'br': None, 'i': R', '/R', '=c+a', 'kt, 'sub': B', 'A', '(t), '()*exp(−),'}, 'c) determining the rate constant of organ clearance of the first molecule (k) from the time series of molecular ratios (R/R)using the equationwherein c is a constant, a is a pre-exponential factor, and t is time;{'sub': C/A', 'C/A', '(t), 'd) administering the test molecule for determination of the metabolic rate and the second molecule to the animal and determining the molecular ratio of the test molecule to the second molecule (R) over a period of time to obtain a time series of molecular ratios of ...

Подробнее

Номер записи: 93

25-04-2013 дата публикации

Diagnostic Method for Atherosclerosis

Номер: US20130101519A1

Автор: Low Philip S.

Принадлежит: PURDUE RESEARCH FOUNDATION

The invention relates to a method of identifying/monitoring active atherosclerotic plaques associated with blood vessel walls wherein the plaques comprise activated macrophages having accessible binding sites for a ligand. The method comprises the steps of administering to a patient being evaluated for atherosclerosis an effective amount of a composition comprising a conjugate of a ligand and a chromophore capable of emitting light under predetermined conditions, allowing sufficient time for the ligand conjugate to bind to the activated macrophages, subjecting the blood vessels to the predetermined conditions using a catheter-based device, and identifying active plaques by detecting light emitted by the chromophore using a catheter-based device or by using an external imaging technique. The invention also relates to a similar method wherein a chemical moiety capable of emitting radiation is conjugated to the ligand. 113.-. (canceled)15. The method of wherein the light emitted by the chromophore is detected using a catheter-based device.16. The method of wherein the light emitted by the chromophore is detected using external imaging.17. The method of wherein the composition is in a parenteral dosage form.18. The method of wherein the parenteral dosage form has a route of administration selected from the group consisting of intradermal claim 17 , subcutaneous claim 17 , intramuscular claim 17 , intraperitoneal claim 17 , and intravenous administration.19. The method of wherein the route of administration is intraperitoneal administration.20. The method of wherein the route of administration is subcutaneous administration.21. The method of wherein the route of administration is intravenous administration.22. The method of wherein the composition comprises a pharmaceutically acceptable carrier.23. The method of wherein the pharmaceutically acceptable carrier is a liquid carrier.24. The method of wherein the liquid carrier is selected from the group consisting of saline ...

Подробнее

Номер записи: 94

25-04-2013 дата публикации

Radiotherapy enhancer

Номер: US20130101680A1

Автор: Masakazu Fukushima

Принадлежит: Individual

The present invention relates to a method of treating pancreatic cancer in a subject in need thereof by administering an effective amount of a composition containing (A) tegafur and (B) gimeracil in conjunction with radiotherapy.

Подробнее

Номер записи: 95

25-04-2013 дата публикации

Modeling of pharmaceutical propagation

Номер: US20130102897A1

Автор: Arthur E. Uber, III, John F. Kalafut

Принадлежит: Medrad Inc

A method of delivering a contrast enhancing fluid to a patient using an injector system, including: determining at least one patient transfer function for the patient based upon data specific to the patient, the at least one patient transfer function providing a time enhancement output for a given input; determining a desired time enhancement output; using the at least one patient transfer function to determine an injection procedure input; and controlling the injector system at least in part on the basis of the determined injection procedure input.

Подробнее

Номер записи: 96

02-05-2013 дата публикации

NEAR-IR INDOCYANINE GREEN DOPED MULTIMODAL SILICA NANOPARTICLES AND METHODS FOR MAKING THE SAME

Номер: US20130108552A1

Автор: BENGTSSON NICLAS, BROWN SCOTT CHANG, GROBMYER STEPHEN R., Iwakuma Nobutaka, MOUDGIL BRIJ M., SANTRA SWADESHMUKUL, SCOTT EDWARD W., SHARMA PARVESH, WALTER GLENN A.

Принадлежит: University of Florida Research Foundation Inc.

The subject invention provides novel fluorescent core-shell nanoparticles comprising an encapsulated fluorescent core comprising an ionically bound fluorescent dye and a metal oxide shell. In one exemplary embodiment of the invention a core containing indocyanine green (ICG) with a silica shell that displays excellent photostability for generation of a near infrared fluorescence signal. The fluorescent core-shell nanoparticle can be further modified to act as an MRI, x-ray, or PAT contrast agent. The ICG nanoparticles can also be used as photodynamic therapeutic agent. Other embodiments of the invention directed to methods of making the novel core-shell nanoparticles and to the use of the core-shell nanoparticles for in vitro or in vivo imaging. 134-. (canceled)35. A fluorescent core-shell nanoparticle comprising:a core comprising a water insoluble matrix with an ionically bound fluorescent dye having at least one anionic sites; anda shell comprising a metal oxide, wherein the nanoparticle is less than 100 nm in diameter.36. The nanoparticle of claim 35 , wherein the metal oxide comprises silicon dioxide.37. The nanoparticle of claim 35 , wherein the water insoluble matrix comprises an ionically crosslinked biocompatible polymer having cationic sites claim 35 , wherein ion-pairing with the fluorescent dye ionically binds the dye within the polymer.38. The nanoparticle of claim 35 , wherein the water insoluble matrix comprises an insoluble salt of a multivalent cation wherein ion-pairing with the fluorescent dye binds the dye within the salt.39. The nanoparticle of claim 35 , wherein the water soluble fluorescent dye is indocyanine green (ICG).40. The nanoparticle of claim 35 , further comprising: a metal deposition on said shell; at least one moiety that exhibits magnetic properties; at least one moiety that exhibits paramagnetic properties; at least one moiety that exhibits X-ray opacity; a contrast agent for photoacoustic tomography (PAT) imaging; or any ...

Подробнее

Номер записи: 97

09-05-2013 дата публикации

GM1-LIKE PEPTIDES AND USES THEREOF

Номер: US20130115170A1

Автор: Usuki Seigo, Wu Han-Chung, Yu Robert

Принадлежит:

Compositions and methods relating to interfering with the interaction of gangliosides, such as GM1, with their ligands are provided. For example, methods are provided for treating infections by blocking the infectious agent from binding with GM1 using GM1-like peptides. Also provided are methods of inhibiting ligands from binding to GM 1 on the surface of cells and for neutralizing anti-GM1 antibodies in neurological diseases. 1. A peptide comprising SEQ ID NO:1 , SEQ ID NO:2 , SEQ ID NO:3 , SEQ ID NO:4 , SEQ ID NO:5 , or SEQ ID NO:6 , or a sequence comprising the amino acids of SEQ ID NO:1 , SEQ ID NO:2 , SEQ ID NO:3 , SEQ ID NO:4 , SEQ ID NO:5 , or SEQ ID NO:6 having one or more conservative substitutions.2. The peptide of claim 1 , wherein the peptide inhibits binding of a ligand to GM1 ganglioside.3. The peptide of claim 2 , wherein the ligand is an antibody or a bacterial protein.4. The peptide of wherein the peptide consists of SEQ ID NO:1 claim 1 , SEQ ID NO:2 claim 1 , SEQ ID NO:3 claim 1 , SEQ ID NO:4 claim 1 , SEQ ID NO:5 claim 1 , or SEQ ID NO:6.5. A composition comprising a peptide of .6. The composition of claim 5 , wherein the peptide mimics the carbohydrate epitope of GM1.7. The composition of claim 5 , wherein the peptide binds cholera toxin B subunit.8. The composition of claim 5 , wherein the peptide binds anti-GM1 antibodies.9. The composition of claim 5 , further comprising a therapeutic agent.10. The composition of claim 5 , further comprising a detectable agent.11. The composition of claim 1 , wherein the peptide is 50 amino acids or less.12. A method of inhibiting binding of a ligand to GM1 comprising administering an effective amount of a GM1-like peptide.13. The method of claim 12 , wherein the ligand is a bacterial protein.14. The method of claim 13 , wherein the bacterial protein is cholera toxin B subunit.15E. coli. The method of claim 13 , wherein the bacterial protein is heat-labile enterotoxin.16. The method of claim 12 , wherein the ...

Подробнее

Номер записи: 98

09-05-2013 дата публикации

MAGNETIC NANOPHOSPHOR HAVING CORE/SHELL STRUCTURE AND THE SYNTHETIC METHOD THEREOF

Номер: US20130115172A1

Автор: JANG Ho Seong, LIM Kipil, WOO Kyoungja

Принадлежит: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

The present invention relates to a nanophosphor and method for synthesizing the same, and provides a nanophosphor containing fluoride-based nanoparticles co-doped with Yb and Er expressed by the following Chemical Formula 1, 1. A nanophosphor comprising fluoride-based nanoparticles co-doped with Yb and Er expressed by the following Chemical Formula 1 ,{'br': None, 'sub': 1−w−z−x−y', 'w', 'z', '4', 'x', 'y, 'sup': 3+', '3+, 'NaYGdLF:Yb,Er\u2003\u2003(1)'}Wherein,x is a real number in the range of 0.1≦x≦0.9; y is a real number in the range of 0 Подробнее

Номер записи: 99

09-05-2013 дата публикации

In-vivo gelling pharmaceutical pre-formulation

Номер: US20130116341A1

Автор: George Horng, Syed H. Askari

Принадлежит: Medicus Biosciences LLC

Provided herein are in vivo gelling pharmaceutical pre-formulations forming biocompatible hydrogel polymers that are polymerized in vivo and kits comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally at least one therapeutic agent. The biocompatible hydrogel polymer is bioabsorbable and releases the therapeutic agent at a target site, avoiding systemic exposure.

Подробнее

Номер записи: 100